• Denali posted a GAAP net loss of $127.6 million, or $0.68 per share, for the quarter ended June 30, 2026.
• Revenue was $3.6 million, reflecting the start of U.S. AVLAYAH sales following FDA approval in March 2026.
• Research and development expense fell 5.55% to $97 million, due to lower small-molecule costs and lower tividenofusp alfa clinical spending.
• Selling, general and administrative expense rose 12.39% to $36.3 million on higher personnel costs tied to the AVLAYAH launch.
• Cash, cash equivalents and marketable securities were about $940 million at quarter-end; a $195 million Priority Review Voucher sale lifted pro forma liquidity above $1.1 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9805519) on August 06, 2026, and is solely responsible for the information contained therein.